Re: Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
Marshall
Fray F
FF
Department of Urology, Emory University School of Medicine, Atlanta, GA, USA. fmarsha@emory.edu